Literature DB >> 27868011

Time to progression ratio: promising new metric or just another metric?

Ming-Wen An1, Sumithra J Mandrekar2.   

Abstract

Year:  2016        PMID： 27868011      PMCID： PMC5104653          DOI： 10.21037/atm.2016.10.21

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  6 in total

1.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

Authors:  Daniel D Von Hoff; Joseph J Stephenson; Peter Rosen; David M Loesch; Mitesh J Borad; Stephen Anthony; Gayle Jameson; Susan Brown; Nina Cantafio; Donald A Richards; Tom R Fitch; Ernesto Wasserman; Cristian Fernandez; Sylvan Green; William Sutherland; Michael Bittner; Arlet Alarcon; David Mallery; Robert Penny
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.

Authors:  Ming-Wen An; Xinxin Dong; Jeffrey Meyers; Yu Han; Axel Grothey; Jan Bogaerts; Daniel J Sargent; Sumithra J Mandrekar
Journal:  J Natl Cancer Inst       Date:  2015-08-21       Impact factor: 13.506

3.  The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.

Authors:  G A Cirkel; F Weeber; S Bins; C G M Gadellaa-van Hooijdonk; E van Werkhoven; S M Willems; M van Stralen; W B Veldhuis; I Ubink; N Steeghs; M J de Jonge; M H G Langenberg; J H M Schellens; S Sleijfer; M P Lolkema; E E Voest
Journal:  Ann Oncol       Date:  2016-05-27       Impact factor: 32.976

4.  Assessing the performance of prediction models: a framework for traditional and novel measures.

Authors:  Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

5.  Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse.

Authors:  Sumithra J Mandrekar; Ming-Wen An; Jeffrey Meyers; Axel Grothey; Jan Bogaerts; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

6.  Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.

Authors:  Ming-Wen An; Yu Han; Jeffrey P Meyers; Jan Bogaerts; Daniel J Sargent; Sumithra J Mandrekar
Journal:  J Clin Oncol       Date:  2015-10-26       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.